Tuesday, January 15, 2008

Ezetimibe Zetia Vytorin - Headless Chicken Award

The Ezetimibe data are out (all those thousands of un-analyzed images that formed the excuse for non release of the results were obviously analyzed at the speed of light). From the WSJ "The long-delayed and much-speculated-about data from Merck and Schering-Plough’s Enhance study comparing whether a combination of Zetia and Zocor works better than Zocor alone were finally released today."

It's a bummer. Time for the first Headless Chicken award of 2008.

Earlier|Later|Main Page


Anonymous said...

From Forbes today:

"ENHANCE lacked many of the safeguards that many clinical trials have, and it seems to have been plagued by problems. Studies often have pre-specified committees that deal with any problems that come up. ENHANCE didn't, and as a result when things went wrong, the companies had to put together a confidential panel on the fly. (See: " Schering and Merck's Secret Panel")"

Yes ENHANCE lacked safeguards - like that the study was carried out by Merck and Schering.

Anonymous said...


Schering-Plough President dumped $28 million SGP stock before Vytorin controversy erupted.

Unknown said...

Hi Aubrey,

I sent Dr. Kastelein a link to your blog. He got a kick out of it. Keep up the good work!


Aubrey Blumsohn said...

Thanks - I wonder whether he will author the paper?